Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Next Previous
Trial Profile

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linavonkibart (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms DRAGON
  • Sponsors Scholar Rock

Most Recent Events

  • 29 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 31 Oct 2024 According to a Scholar Rock media release, data from this study will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston on November 6-10.
  • 04 Jun 2024 Updated results of expansion part (as of 12 Jan 2024, n= 72) presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top